May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Long-Term Efficacy and Safety of Botulinum Toxin Injetions
Author Affiliations & Notes
  • A. Cetinkaya
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio
  • O. Ababneh
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio
  • P. A. Brannan
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio
  • D. R. Kulwin
    Ophthalmology, University of Cincinnati, Cincinnati, Ohio
  • Footnotes
    Commercial Relationships A. Cetinkaya, None; O. Ababneh, None; P.A. Brannan, None; D.R. Kulwin, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5490. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Cetinkaya, O. Ababneh, P. A. Brannan, D. R. Kulwin; Long-Term Efficacy and Safety of Botulinum Toxin Injetions. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5490.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: This study is designed to determine the efficacy and safety of botulinum toxin A (BOTOX) injections after 10 years of treatment.

Methods:: Medical records of 64 consecutive patients who received BOTOX injections between 10/2005 and 05/2006 were retrospectively reviewed. Patients treated for more than 10 years with at least 1 injection each year were included in the study. Clinical diagnoses, patient characteristics, injection dates and doses, peak effect durations, and adverse effects were collected. Response ratings were obtained using a subjective self-evaluation scale of 0-4. Statistical analyses were conducted with SPSS 11.0 package. Wilcoxon signed-rank test was used for computations (p<0.05 accepted as statistically significant).

Results:: Thirty-two out of 64 patients (mean age, 57.6±12.3 years; 25 female) met the inclusion criteria. The diagnoses were benign essential blepharospasm (BEB) (n=21), hemifascial spasm (HFS) (n=9), myokymia (n=1), and Bell’s palsy (n=1). Only one eye of each patient was evaluated for statistical analysis. The mean follow-up duration was 14±4 years (range; 10-19.5), with a mean of 44.7±19.3 total visits. The patients received 3.5±1.5 and 3.3±1.1 treatments per year during first and the last years, respectively (p=0.253). A higher mean injection dose units per visit (26.4±10.3) was used in the last year, compared to first year (22.6±7.6) (p<0.005). The mean peak effect durations for the first and last years were, 12.6±7.1 and 14.5±7.1 weeks, respectively (p=0.116). There was no difference in response ratings for the first (3.3± 0.6) and last (3.4± 0.5) years (p=0.395). Most common adverse effects noted during the mean 14 years of follow-up were ptosis (13 from 12 patients), lagophthalmos (12 from 11 patients), and dry eye (12 from 12 patients). Twelve of these events were reported during the 1st year, 18 between 1 and 10 years, and only 7 events after 10 years. Other rare side effects were diplopia (n=4), ectropion (n=3), hematoma (n=2), photophobia (n=2), and continuous nasal discharge (n=1). None of these reactions were life-threatening.

Conclusions:: BOTOX provides a satisfactory and safe long-term treatment after 10 years of continuous use. Similar efficacy of treatment, requiring higher doses of injections, comes with diminished adverse effects.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: systems/equipment/techniques • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.